Diagnosis of Clostridium difficile infection: the molecular approach

Future Microbiology

Volumn 8, Issue 12, 2013, Pages 1587-1598

  Eckert, Catherine ^a,b   Jones, Gabrielle ^c   Barbut, Frederic ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c University of Paris Cité   (France)

Author keywords

Clostridium difficile; diagnostic; diarrhea; molecular methods; NAAT; PCR

Indexed keywords

GLUTAMATE DEHYDROGENASE; METRONIDAZOLE; VANCOMYCIN;

ALGORITHM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL STRAIN; BACTERIUM CULTURE; CLOSTRIDIUM DIFFICILE INFECTION; COST; CYTOTOXICITY TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DNA EXTRACTION; DNA MODIFICATION; ENZYME IMMUNOASSAY; FECES ANALYSIS; GENOTYPE; HOSPITALIZATION; HUMAN; IMMUNOREACTIVITY; LABORATORY TEST; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; META ANALYSIS (TOPIC); MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID AMPLIFICATION TEST; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK FACTOR; STOOL CYTOTOXICITY ASSAY; TOXIGENIC CULTURE; TOXIN ANALYSIS; TURNAROUND TIME;

ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

EID: 84889587460     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.129     Document Type: Review

References (81)

1. Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: A European perspective. J. Infect. 66(2), 115-128 (2013).
2. Gerding DN. Clostridium difficile 30 years on: What has, or has not, changed and why? Int. J. Antimicrob. Agents 33(Suppl. 1), S2-S8 (2009).
3. Planche T, Wilcox M. Reference assays for Clostridium difficile infection: One or two gold standards? J. Clin. Pathol. 64(1), 1-5 (2011).
4. Larson HE, Barclay FE, Honour P, Hill ID. Epidemiology of Clostridium difficile in infants. J. Infect. Dis. 146(6), 727-733 (1982). (Pubitemid 13211868)
5. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: Evidence for colonized new admissions as a source of infection. J. Infect. Dis. 166(3), 561-567 (1992).
6. Bartlett JG. Detection of Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 31(Suppl. 1), S35-S37 (2010).
7. Bignardi GE. Risk factors for Clostridium difficile infection. J. Hosp. Infect. 40(1), 1-15 (1998). (Pubitemid 28438966)
8. Hensgens MPM, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J. Antimicrob. Chemother. 67(3), 742-748 (2012).
9. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir O, Bjornsson ES. Risk factors for Clostridium difficile toxin-positive diarrhea: A population-based prospective case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 31(10), 2601-2610 (2012).
10. Loo VG, Bourgault A-M, Poirier L et al. Host and pathogen factors for Clostridium difficile infection and colonization. N. Engl. J. Med. 365(18), 1693-1703 (2011).
11. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467(7316), 711-713 (2010).
12. Braun V, Hundsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 181(1-2), 29-38 (1996). (Pubitemid 26418243)
13. Dupuy B, Govind R, Antunes A, Matamouros S. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J. Med. Microbiol. 57(Pt 6), 685-689 (2008). (Pubitemid 351842058)
14. Mani N, Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc. Natl Acad. Sci. USA 98(10), 5844-5849 (2001). (Pubitemid 32435730)
15. Popoff MR, Rubin EJ, Gill DM, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect. Immun. 56(9), 2299-2306 (1988).
16. Eckert C, Coignard B, Hebert M et al. Clinical and microbiological features of Clostridium difficile infections in France: The ICD-RAISIN 2009 national survey. Med. Mal. Infect. 43(2), 67-74 (2013).
17. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-Associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 171(5), 466-472 (2004). (Pubitemid 39179608)
18. Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-Associated disease in North America and Europe. Clin. Microbiol. Infect. 12(Suppl. 6), 2-18 (2006). (Pubitemid 44362038)
19. Loo VG, Poirier L, Miller MA et al A predominantly clonal multi-institutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N. Engl J Med. 353, 2442-2449 (2005). (Pubitemid 41770165)
20. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433-2441 (2005). (Pubitemid 41770164)
21. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366(9491), 1079-1084 (2005). (Pubitemid 41338761)
22. Arvand M, Moser V, Schwehn C, Bettge-Weller G, Hensgens MP, Kuijper EJ. High prevalence of Clostridium difficile colonization among nursing home residents in Hesse, Germany. PLoS ONE 7(1), e30183 (2012).
23. Symposia and oral presentations. Clin. Microbiol. Infect. 18(Suppl. 3), 1-113 (2012).
24. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-Associated Clostridium difficile infection. J. Antimicrob. Chemother. 62(2), 388-396 (2008). (Pubitemid 351984787)
25. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nat. Rev. 7(7), 526-536 (2009)
26. Avbersek J, Janezic S, Pate M et al. Diversity of Clostridium difficile in pigs and other animals in Slovenia. Anaerobe 15(6), 252-255 (2009).
27. Hensgens MP, Keessen EC, Squire MM et al. Clostridium difficile infection in the community: A zoonotic disease? Clin. Microbiol. Infect. 18(7), 635-645 (2012).
28. Dodek PM, Norena M, Ayas NT, Romney M, Wong H. Length of stay and mortality due to Clostridium difficile infection acquired in the intensive care unit. J. Crit. Care 28(4), 335-340 (2013).
29. Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S. Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-Associated diarrhea. J. Med. Econ. 16(3), 440-448 (2013).
30. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23(3), 529-549 (2010).
31. Tenover FC, Baron EJ, Peterson LR, Persing DH. Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J. Mol. Diagn. 13(6), 573-582 (2011).
32. Wilcox MH. Laboratory diagnosis of Clostridium difficile infection: In a state of transition or confusion or both? J. Hosp. Infect. 79(1), 1-3 (2011).
33. Carroll KC, Loeffelholz M. Conventional versus molecular methods for the detection of Clostridium difficile. J. Clin. Microbiol. 49(Suppl. 9), S49-S52 (2011).
34. Chapin K. Discrepancies in testing recommendations for Clostridium difficile infection: Updated review favors amplification test systems. Expert Rev. Mol. Diagn. 12(3), 223-226 (2012).
35. Wilcox MH. Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin. Microbiol. Infect. 18, 13-20 (2012).
36. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15(12), 1067-1079 (2009).
37. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control. Hosp. Epidemiol. 31(5), 431-455 (2010).
38. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351(9103), 633-636 (1998). (Pubitemid 28098446)
39. Johnson S, Homann SR, Bettin KM et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann. Intern. Med. 117(4), 297-302 (1992).
40. van den Berg RJ, Vaessen N, Endtz HP, Schulin T, van der Vorm ER, Kuijper EJ. Evaluation of real-Time PCR and conventional diagnostic methods for the detection of Clostridium difficile-Associated diarrhoea in a prospective multicentre study. J. Med. Microbiol. 56(Pt 1), 36-42 (2007). (Pubitemid 46036272)
41. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect. Control. Hosp. Epidemiol. 31(1), 21-27 (2010).
42. Aichinger E, Schleck CD, Harmsen WS, Nyre LM, Patel R. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J. Clin. Microbiol. 46(11), 3795-3797 (2008).
43. Barbut F, Lalande V, Eckert C. New molecular methods for the diagnosis of Clostridium difficile infections. Drugs Today 48(10), 673-684 (2012).
44. Chang TW, Gorbach SL, Bartlett JB. Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect. Immun. 22(2), 418-422 (1978). (Pubitemid 9052614)
45. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin. Microbiol. Infect. 15(12), 1053-1066 (2009).
46. Sullivan NM, Pellett S, Wilkins TD. Purification and characterization of toxins A and B of Clostridium difficile. Infect. Immun. 35(3), 1032-1040 (1982).
47. Maniar AC, Williams TW, Hammond GW. Detection of Clostridium difficile toxin in various tissue culture monolayers. J. Clin. Microbiol. 25(10), 1999-2000 (1987). (Pubitemid 17149285)
48. Ryder AB, Huang Y, Li H et al. Assessment of Clostridium difficile infections by quantitative detection of TcdB toxin by use of a real-Time cell analysis system. J. Clin. Microbiol. 48(11), 4129-4134 (2010).
49. Bouza E, Pela ́ez T, Alonso R, Catala ́n P, Muñoz P, Cre ́ixems MR. "Second-look" cytotoxicity: An evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. J. Hosp. Infect. 48(3), 233-237 (2001). (Pubitemid 32680863)
50. George WL, Sutter VL, Citron D, Finegold SM. Selective and differential medium for isolation of Clostridium difficile. J. Clin. Microbiol. 9(2), 214-219 (1979). (Pubitemid 9123787)
51. Wilcox MH, Fawley WN, Parnell P. Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery of Clostridium difficile. J. Hosp. Infect. 44(1), 65-69 (2000). (Pubitemid 30074338)
52. Foster NF, Riley TV. Improved recovery of Clostridium difficile spores with the incorporation of synthetic taurocholate in cycloserine-cefoxitin- fructose agar (CCFA). Pathology 44(4), 354-356 (2012).
53. Eckert C, Burghoffer B, Lalande V, Barbut F. Evaluation of the chromogenic agar chromID C. difficile. J. Clin. Microbiol. 51(3), 1002-1004 (2013).
54. Marler LM, Siders JA, Wolters LC, Pettigrew Y, Skitt BL, Allen SD. Comparison of five cultural procedures for isolation of Clostridium difficile from stools. J. Clin. Microbiol. 30(2), 514-516 (1992).
55. Shetty N, Wren MWD, Coen PG. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: A meta-Analysis. J. Hosp. Infect. 77(1), 1-6 (2011).
56. Tenover FC, Novak-Weekley S, Woods CW et al. Impact of strain type on detection of toxigenic Clostridium difficile: Comparison of molecular diagnostic and enzyme immunoassay approaches. J. Clin. Microbiol. 48(10), 3719-3724 (2010).
57. Goldenberg SD, Gumban M, Hall A, Patel A, French GL. Lack of effect of strain type on detection of toxigenic Clostridium difficile by glutamate dehydrogenase and polymerase chain reaction. Diagn. Microbiol. Infect. Dis. 70(3), 417-419 (2011).
58. Carman RJ, Wickham KN, Chen L et al. Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes. J. Clin. Microbiol. 50(4), 1425-1426 (2012).
59. Rene ́ P, Frenette CP, Schiller I et al. Comparison of eight commercial enzyme immunoassays for the detection of Clostridium difficile from stool samples and effect of strain type. Diagn. Microbiol. Infect. Dis. 73(1), 94-96 (2012).
60. Culbreath K, Ager E, Nemeyer RJ, Kerr A, Gilligan PH. Evolution of testing algorithms at a university hospital for detection of Clostridium difficile infections. J. Clin. Microbiol. 50(9), 3073-3076 (2012).
61. Goldenberg SD, Cliff PR, French GL. Glutamate dehydrogenase for laboratory diagnosis of Clostridium difficile infection. J. Clin. Microbiol. 48(8), 3050-3051; author reply 3051 (2010).
62. O'Horo JC, Jones A, Sternke M, Harper C, Safdar N. Molecular techniques for diagnosis of Clostridium difficile infection: Systematic review and meta-Analysis. Mayo Clin. Proc. 87(7), 643-651 (2012).
63. Deshpande A, Pasupuleti V, Rolston DD et al. Diagnostic accuracy of real-Time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: A meta-Analysis. Clin. Infect. Dis. 53(7), e81-e90 (2011).
64. Vasoo S, Stevens J, Portillo L et al. Cost-effectiveness of a modified two-step algorithm using a combined glutamate dehydrogenase/toxin enzyme immunoassay and real-Time PCR for the diagnosis of Clostridium difficile infection. J. Microbiol. Immunol. Infect. doi:10.1016/j. jmii.2012.07.008 (2012) (Epub ahead of print).
65. Gerding DN, Olson MM, Peterson LR et al. Clostridium difficile-Associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch. Intern. Med. 146(1), 95-100 (1986). (Pubitemid 16158635)
66. Polage CR, Chin DL, Leslie JL, Tang J, Cohen SH, Solnick JV. Outcomes in patients tested for Clostridium difficile toxins. Diagn. Microbiol. Infect. Dis. 74(4), 369-373 (2012).
67. Ryan J, Murphy C, Twomey C et al. Asymptomatic carriage of Clostridium difficile in an Irish continuing care institution for the elderly: Prevalence and characteristics. Ir. J. Med. Sci. 179(2), 245-250 (2010).
68. Guerrero DM, Chou C, Jury LA, Nerandzic MM, Cadnum JC, Donskey CJ. Clinical and infection control implications of Clostridium difficile infection with negative enzyme immunoassay for toxin. Clin. Infect. Dis. 53(3), 287-290 (2011).
69. Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J. Clin. Microbiol. 51(3), 869-873 (2013).
70. Longtin Y, Trottier S, Brochu G et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin. Infect. Dis. 56(1), 67-73 (2013).
71. Planche TD, Davies KA, Coen PG et al. Clinical validation of Clostridium difficile infection (CDI) diagnostics: Importance of toxin detection. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 9-12 September 2012 (Abstract D-160).
72. Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection. Updated Guidance on the Diagnosis and Reporting of Clostridium difficile. Department of Health, London, UK (2012).
73. Fong KS, Fatica C, Hall G et al. Impact of PCR testing for Clostridium difficile on incident rates and potential on public reporting: Is the playing field level? Infect. Control. Hosp. Epidemiol. 32(9), 932-933 (2011).
74. Goldenberg SD. Public reporting of Clostridium difficile and improvements in diagnostic tests. Infect. Control. Hosp. Epidemiol. 32(12), 1231-1232; author reply 1233 (2011).
75. Carroll KC. Tests for the diagnosis of Clostridium difficile infection: The next generation. Anaerobe 17(4), 170-174 (2011).
76. Barbut F, Surgers L, Eckert C et al. Does a rapid diagnosis of Clostridium difficile infection impact on quality of patient management? Clin. Microbiol. Infect. doi:10.1111/1469-0691.12221 (2013) (Epub ahead of print).
77. Johnson SW, Kanatani M, Humphries RM, Uslan DZ. Clinical impact of switching conventional enzyme immunoassay with nucleic acid amplification test for suspected Clostridium difficile-Associated diarrhea. Am. J. Infect. Control. 41(4), 373-375 (2012).
78. Sydnor ER, Lenhart A, Trollinger B et al. Antimicrobial prescribing practices in response to different Clostridium difficile diagnostic methodologies. Infect. Control. Hosp. Epidemiol. 32(11), 1133-1136 (2011).
79. Catanzaro M, Cirone J. Real-Time polymerase chain reaction testing for Clostridium difficile reduces isolation time and improves patient management in a small community hospital. Am. J. Infect. Control. 40(7), 663-666 (2012).
80. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108(4), 478-498 (2013).
81. Dubberke ER, Han Z, Bobo L et al. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J. Clin. Microbiol. 49(8), 2887-2893 (2011).